MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

Future Oncol. 2022 Jun;18(20):2465-2473. doi: 10.2217/fon-2022-0093. Epub 2022 May 10.


Standard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) chemotherapy. Early-phase clinical studies support further clinical development of the immune checkpoint inhibitor (ICI); durvalumab, an anti-PD-L1 antibody, in patients with gastric/gastroesophageal junction cancer. Accumulating evidence indicates that ICIs combined with FLOT chemotherapy improve clinical outcomes in patients with advanced or metastatic cancer. We describe the rationale for and the design of MATTERHORN, a randomized, double-blind, placebo-controlled, phase III study investigating the efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy followed by adjuvant durvalumab monotherapy in patients with resectable gastric/gastroesophageal junction cancer. The planned sample size is 900 patients, the primary end point is event-free survival and safety and tolerability will be evaluated. Clinical trial registration: NCT04592913 (

Keywords: PD-L1; chemotherapy; durvalumab; gastric cancer; gastroesophageal junction cancer; immune checkpoint inhibitors; immunotherapy; neoadjuvant-adjuvant; resectable.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma* / pathology
  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Clinical Trials, Phase III as Topic
  • Esophagogastric Junction / pathology
  • Fluorouracil / adverse effects
  • Humans
  • Neoadjuvant Therapy
  • Randomized Controlled Trials as Topic
  • Stomach Neoplasms* / pathology


  • Antibodies, Monoclonal
  • durvalumab
  • Fluorouracil

Associated data


Grants and funding